To Sleeve or Not to Sleeve: Validation of Liver Transplantation with Sleeve Gastrectomy [0.03%]
套管还是不用套管：胃 sleeve 成形术肝移植的验证研究
Linda W Moore,Elizabeth W Brombosz,R Mark Ghobrial
Linda W Moore
Diving deep: finding pathogenic intronic variants and making them actionable [0.03%]
深度挖掘：寻找致病的内含子变异并将其付诸行动
Benedikt Schaefer,Heinz Zoller
Benedikt Schaefer
Machine learning based radiomic models outperform clinical biomarkers in predicting outcomes after immunotherapy for hepatocellular carcinoma [0.03%]
基于机器学习的影像组学模型可更好地区分接受免疫治疗后的肝细胞癌患者的预后
Mathew Vithayathil,Deniz Koku,Claudia Campani et al.
Mathew Vithayathil et al.
Background: Atezolizumab plus bevacizumab (A/B) is a first-line therapy for unresectable hepatocellular carcinoma (HCC). Only a small proportion of patients respond to treatment. This study integrated radiomic and clinica...
Regulation of KIF23 by miR-107 controls replicative tumor cell fitness in mouse and human hepatocellular carcinoma [0.03%]
miR-107通过调节KIF23控制小鼠和人类肝细胞癌的增殖性肿瘤细胞适应度
Mirco Castoldi,Sanchari Roy,Carolin Angendohr et al.
Mirco Castoldi et al.
Background & aims: In hepatocellular carcinoma (HCC), successful translation of experimental targets identified in mouse models to human patients has proven challenging. In this study, we used a comprehensive transcriptom...
Follow-up NIT values rather than their variation predict hepatocellular carcinoma after HCV eradication [0.03%]
HCV患者治愈后跟进NIT值而非其变化可预测肝细胞癌
Flavia Ferreira Fernandes,Paula Guedes Ferreira da Silva,Cristiane Alves Villela Nogueira
Flavia Ferreira Fernandes
Validation and expansion of Baveno VII recompensation criteria in patients with cirrhosis and curable liver disease [0.03%]
Baveno VII代偿期肝硬化和可治愈性肝病患者标准的验证与扩展
Marta Tonon,Roberta Gagliardi,Enrico Pompili et al.
Marta Tonon et al.
Background and aims: Baveno-VII consensus recently defined recompensation in patients with decompensated cirrhosis achieving etiological cure. However, incidence, predictors and clinical significance of recompensation are...
Phosphatidylethanol levels distinguish steatotic liver disease subgroups and are associated with risk of major liver outcomes [0.03%]
磷脂酰乙醇水平可区分肝脂肪变性疾病亚型并与主要肝脏不良结局的风险相关
Juan Vaz,Patrik Nasr,Anders Helander et al.
Juan Vaz et al.
Background & aims: Phosphatidylethanol (PEth) is an ethanol metabolite used as a specific biomarker for recent alcohol consumption. We aimed to determine the proportion of patients with or at risk for metabolic dysfunctio...
Critical Analysis of Statistical Methods in Albumin Treatment Study: Advocating for Nonlinear Approaches in Biological Data Analysis [0.03%]
白蛋白治疗研究的统计方法批判：提倡生物数据分析中的非线性方法
Yoshiyasu Takefuji
Yoshiyasu Takefuji
Five-year overall survival update from the HIMALAYA study of tremelimumab plus durvalumab in unresectable HCC [0.03%]
HIMALAYA研究：Tremelimumab联合Durvalumab治疗不可切除肝细胞癌的五年总生存期更新数据
Lorenza Rimassa,Stephen L Chan,Bruno Sangro et al.
Lorenza Rimassa et al.
Background & aims: In the phase III HIMALAYA study (NCT03298451), STRIDE (Single Tremelimumab Regular Interval Durvalumab) significantly improved overall survival (OS) versus sorafenib in unresectable HCC (uHCC) and demon...